Does CT Showing Mild Adrenal Thickening Need Any Work Up?
Yes, mild adrenal thickening on CT requires both biochemical evaluation and imaging characterization to exclude hormone excess and malignancy, regardless of how "mild" it appears.
Initial Approach: Two-Pronged Evaluation
The 2025 Endocrine Practice guidelines emphasize that comprehensive clinical and biochemical assessment alongside imaging is critical for all patients with an adrenal lesion 1. This applies even to subtle findings like "mild thickening."
1. Biochemical Workup (Required for All)
All patients must be screened for hormone excess, even if asymptomatic 1:
- 1-mg dexamethasone suppression test - to exclude mild autonomous cortisol secretion (MACS), which occurs in up to 30% of incidentalomas and increases cardiovascular mortality 1, 2
- Plasma or 24-hour urinary metanephrines - to exclude pheochromocytoma (critical for patient safety) 2
- Aldosterone-to-renin ratio - if patient has hypertension or hypokalemia 2
Key caveat: The only exception to pheochromocytoma screening is if you have unequivocal adenoma confirmed on unenhanced CT with attenuation ≤10 HU AND no adrenergic symptoms 2. Since you have "thickening" (not a discrete mass with measured HU), you cannot skip this screening.
2. Imaging Characterization
The imaging approach depends on whether this represents diffuse thickening versus a discrete lesion:
If Discrete Lesion >1 cm:
Obtain non-contrast CT (NCCT) if not already done to measure Hounsfield units 1:
- ≤10 HU: Benign adenoma, no further imaging needed if <4 cm 1, 2
- 11-20 HU and <4 cm: Obtain second-line imaging (adrenal protocol CT with washout, chemical shift MRI, or PET-CT) 1, 2
- >20 HU or heterogeneous: High malignancy risk, requires multidisciplinary discussion 1
- ≥4 cm even if benign-appearing: Repeat imaging in 6-12 months due to higher malignancy risk (6% for 4-6 cm lesions) 1, 2
If Bilateral Thickening:
Bilateral findings require heightened vigilance 1:
- More likely to have hormone excess than unilateral lesions 1
- Must assess for primary adrenal insufficiency if considering metastases, lymphoma, granulomatous disease, hemorrhage, or infarction 1
- Screen with 17-hydroxyprogesterone if bilateral hyperplasia to exclude congenital adrenal hyperplasia 1
- Research shows bilateral nodules in patients without cancer have extremely low malignancy rates (0% in one 161-patient study), but functional workup remains essential 3
Follow-Up Strategy
For Indeterminate Lesions:
- Repeat imaging in 6-12 months with NCCT or MRI 1
- Growth ≥5 mm/year warrants surgical consideration after repeating functional workup 2
- Growth <3 mm/year requires no further imaging 2
- Stability for 12 months generally indicates benignity, but hormone excess must still be excluded 1
For Benign-Appearing Lesions <4 cm:
No further imaging or functional testing needed if confirmed benign (≤10 HU) and non-functional 2
Critical Pitfalls to Avoid
Never assume "mild" means benign - MACS and pheochromocytomas can appear subtle but cause significant morbidity/mortality 1
Don't skip pheochromocytoma screening unless you have definitive adenoma (≤10 HU) - missing this diagnosis can be fatal during surgery or cause hypertensive crisis 2
Bilateral findings are not reassuring - they actually increase likelihood of hormone excess and require more thorough evaluation 1
Age matters - patients <40 years have higher malignancy risk and require urgent MRI assessment 1
Prior malignancy changes everything - even if adrenal finding seems incidental, up to 70% of indeterminate lesions in cancer patients are malignant 1
Special Populations
- Patients <40 years or pregnant: Urgent MRI preferred, consider surgery for non-characteristically benign lesions 1
- History of extra-adrenal malignancy: Still screen for pheochromocytoma even if metastasis suspected, as imaging cannot reliably differentiate 1
Bottom line: "Mild adrenal thickening" is not a reason to defer workup. The combination of biochemical screening and proper imaging characterization is mandatory to prevent missing life-threatening conditions like pheochromocytoma or clinically significant hormone excess that increases cardiovascular mortality.